Synonym
BRN 2012594; M 25; LS72312; Z6202; M 256202; M256202.
IUPAC/Chemical Name
2-[[bis(2-chloroethyl)amino-[(2-ethoxy-2-oxoethyl)amino]phosphanyl] amino]acetate
InChi Key
IOBSTYBMPYRWQR-UHFFFAOYSA-M
InChi Code
InChI=1S/C10H20Cl2N3O4P/c1-2-19-10(18)8-14-20(13-7-9(16)17)15(5-3-11)6-4-12/h13-14H,2-8H2,1H3,(H,16,17)/p-1
SMILES Code
O=C([O-])CNP(N(CCCl)CCCl)NCC(OCC)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
The antitumor activity of oral glyciphosphoramide was demonstrated in tumor-bearing animals (mice, rats, and dogs). In mice, the LD50 for oral and i.p. I were 580 and 360 mg/kg, resp. The max. tolerated dose of I in dogs was 20 mg/kg/day. In normal rats, 14C-radioactivity in blood reached its peak 8 h after oral administration of I-14C. The tissue distribution of I-14C in normal and tumor-bearing rats was similar, the radioactivity being highest in liver, kidney, and gastrointestinal tract and tumor tissue. The cumulative excretion of 14C-radioactivity in urine and feces was 32.54% within 96 h. see: Zhongguo Yixue Kexueyuan Xuebao (1984), 6(5), 334-7.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
376.21
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Wang WJ, Bai JY, Zhu XY. [Determination of glyciphosphoramide and its metabolite in plasma and the pharmacokinetics in rats after oral administration]. Yao Xue Xue Bao. 1993;28(10):738-43. Chinese. PubMed PMID: 8009985.
2: He S, Ji XJ, Zhu TX, Wang NG, Su XL, Cao FZ, Pan ZK, Li ZR, Bao TT, Han R. [A study of the antitumor action of glyciphosphoramide]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1984 Oct;6(5):334-7. Chinese. PubMed PMID: 6241082.
3: Sun Y. [Clinical phase II trial of a new antineoplastic drug, glyciphosphoramide (GPM)]. Zhonghua Zhong Liu Za Zhi. 1984 Sep;6(5):375-8. Chinese. PubMed PMID: 6534723.
4: Wang ZY. [Clinical evaluation of glyciphosphoramide used alone and in combination with other drugs]. Zhonghua Zhong Liu Za Zhi. 1984 Sep;6(5):379-81. Chinese. PubMed PMID: 6398774.
5: Guo JY, Huang L, Tian SH, Zhao QR. [Synthesis of the 14C labelled anticancer agent: N,N-bis(beta-chloroethyl)-N',N"-di(carboethoxy-[14C] methyl)-phosphorotriamide]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1984 Aug;6(4):295-7. Chinese. PubMed PMID: 6241072.
6: Sun Y. [Clinical phase II trial of a new antineoplastic drug--glyciphosphoramide]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1984 Aug;6(4):273-6. Chinese. PubMed PMID: 6241067.
7: Sun Y. [Clinical phase I trial of a new anti-neoplastic drug--glyciphosphoramide]. Zhonghua Zhong Liu Za Zhi. 1984 Jul;6(4):293-5. Chinese. PubMed PMID: 6525950.
